Atlas Trials

Chugai Pharmaceutical

63 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Chugai Pharmaceutical

RecordFirmDate
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer (NCT07617337)Chugai Pharmaceutical2026-07-31
A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (NCT07107490)Chugai Pharmaceutical2025-10-08
Study of AUBE00 in Patients With Solid Tumors (NCT07030959)Chugai Pharmaceutical2025-06-05
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) (NCT06723106)Chugai Pharmaceutical2024-12-09
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) (NCT06371417)Chugai Pharmaceutical2024-08-19
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors (NCT05907980)Chugai Pharmaceutical2023-05-24
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (NCT05735366)Chugai Pharmaceutical2023-04-17
A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study) (NCT05686369)Chugai Pharmaceutical2023-03-08
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients (NCT05425446)Chugai Pharmaceutical2022-09-19
Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis (NCT05433207)Chugai Pharmaceutical2022-08-01
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). (NCT05012618)Chugai Pharmaceutical2021-10-08
An Observational Study of Patients With Endometriosis to Evaluate the Usefulness of the MEDL Score, a New Method for Evaluating Endometriosis Using MRI (NCT04846582)Chugai Pharmaceutical2021-07-28
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma (NCT05022927)Chugai Pharmaceutical2021-06-01
The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2) (NCT04818983)Chugai Pharmaceutical2021-04-07
Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371 (NCT04649216)Chugai Pharmaceutical2020-11-25
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). (NCT04511845)Chugai Pharmaceutical2020-09-10
Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2) (NCT04501497)Chugai Pharmaceutical2020-08-21
A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism (NCT04209179)Chugai Pharmaceutical2020-07-23
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC (NCT04097444)Chugai Pharmaceutical2019-10-11
PD-L1 Expression in Japanese Renal Cell Carcinoma Patients (NCT03748901)Chugai Pharmaceutical2018-12-16
A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL) (NCT03645330)Chugai Pharmaceutical2018-08-15

Track Chugai Pharmaceutical automatically

Every clearance here is in the API, with alerts when new ones post.